Well Referenced

Tag: adverse effects

Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study)

This randomized controlled trial (LOMAGHI Study) compared low-dose (4.5 g) versus high-dose (9 g) intravenous magnesium sulfate (MgSO₄) and placebo in 450 adults presenting to the emergency department with rapid atrial fibrillation (AF). All participants received standard AV nodal blockers. At 4 hours, therapeutic response was higher in the magnesium

Read More »
June 26, 2025 No Comments

Usefulness of Beta blockade in contemporary management of patients with stable coronary heart disease

This observational study examined the effectiveness of beta-blockers in patients with stable coronary heart disease (CHD), suggesting that their routine use in all stable CHD patients may not be necessary. While beta-blockers significantly reduce mortality and recurrent cardiovascular events in patients with recent myocardial infarction or heart failure, their benefits

Read More »
June 26, 2025 No Comments

Locally advanced prostate cancer: effective treatments, but many adverse effects

A review published in Lancet Oncology (2008) examined treatments for locally advanced prostate cancer, including prostatectomy, external beam radiation therapy (EBRT) combined with gonadorelin agonists, and androgen suppression. The study found that prostatectomy has a 2% to 16% cancer-specific mortality rate over five years, but with significant side effects like

Read More »
June 26, 2025 No Comments

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer

This systematic review evaluated the effectiveness and cost-effectiveness of various androgen suppression therapies for advanced prostate cancer, comparing monotherapy options such as orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, and antiandrogens to combined androgen blockade (CAB), while also examining the timing of therapy initiation (immediate vs. deferred). The study found that

Read More »
June 26, 2025 No Comments

Chelation therapy in cardiovascular disease: an update

The article reviews the efficacy of chelation therapy in cardiovascular disease, particularly following myocardial infarction (MI), and highlights the potential benefits observed in specific subgroups, such as diabetic patients. It discusses findings from the Trial to Assess Chelation Therapy (TACT), which suggested some reduction in cardiovascular events but acknowledged the

Read More »
June 26, 2025 No Comments

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer’s dementia

This randomized controlled trial investigated the effects of acetyl-L-carnitine (ALC) on cognitive function in patients with Alzheimer’s-type dementia. While no statistically significant differences were observed between the ALC and placebo groups, trends suggested potential benefits in short-term memory, as measured by the Names Learning Test and Digit Recall Test. Additionally,

Read More »
June 26, 2025 No Comments

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea

Read More »
June 26, 2025 No Comments

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response

This randomized controlled trial investigated the effects of combining low-dose intranasal PT-141 (bremelanotide) with sildenafil in 19 men with erectile dysfunction (ED). The study found that the combination significantly enhanced erectile response during visual sexual stimulation compared to sildenafil alone, without increasing adverse events. PT-141, a melanocortin receptor agonist, acts

Read More »
June 26, 2025 No Comments